Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

University Of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed By Standard Hybridization Test
Results from a study published by the University of Michigan have shown that as many as 15% of women in the study group determined to be negative for the presence of human papillomavirus (HPV) in the cervix, via the most commonly used test for HPV DNA, may actually be infected with the virus at clinically relevant viral loads. PCR-MS detected the presence of high-risk HPV in nearly half (46.7%) of women who tested negative by the Hybrid Capture 2 (HC2) test, which is standard of care in many countries. Approximately 9,000 American women are diagnosed with cervical cancer each year despite regular cervical screening. The study, titled, Development and Evaluation of a PCR and Mass Spectroscopy-based (PCR-MS) Method for Quantitative, Type-specific Detection of Human Papillomavirus, will be published in the September 2009 edition of Journal of Virological Methods. The assay used in this study is exclusively licensed by SEQUENOM (Nasdaq: SQNM).
new payday loan lenders
Obama Campaign Contributors Being Asked To Donate To Effort Supporting Health Care Reform
The Washington Times on Friday examined how President Obama"s "former campaign apparatus is cranking up a full-tilt drive for passage of a health care overhaul this year" by "tapping his 13-million-strong e-mail list" for financial contributions to fund advertising efforts, hire staff and open election-style offices. The group -- launched in January as Organizing for America, or OFA2, a unit under the Democratic National Committee -- sent supporters an e-mail this week asking them for their time and money to fight "special interest lobbyists and partisan ideologues" that might attempt to "water down" health care reform. Mitch Stewart, the group"s executive director, wrote that contributions would be used to organize "local educational events" and to "bring constituent voices straight to Congress, and make sure real life stories are heard louder than the lobbyists" spin" (Bellantoni, Washington Times, 5/15). Single-Payer System Not on Table, Obama Says
News of the day
Phase 3 Trial Initiated To Evaluate Combination Therapy Of Nexavar(R) And Tarceva(R) In Patients With Liver Cancer
Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
Cardiovascular

Chinese Women Join Global Breast Cancer Trial

Breast cancer patients have for the first time been recruited from China to take part in an international trial of breast radiotherapy. Researchers will evaluate how effective the treatment is for women who have had a mastectomy. Radiotherapy works by destroying cancer cells in the treated area. The trial will investigate whether the treatment lessens the risk of the cancer returning in patients who have had a breast removed. The results of the trial will be highly relevant in China, where breast cancer is becoming a major health care issue, particularly in urban populations. The trial represents the first time that international breast cancer research has included Chinese patients and opens the door to future collaborations. Some 3700 breast cancer patients from Europe, Australia, Singapore, Japan and China will take part in the trial, led by the University of Edinburgh. Chinese patients will be recruited from nine cancer centres across the country and will be randomly assigned one of two possible courses of treatment - one to include standard post-operative care such as outpatient visits and mammogram check-ups, and another, which includes all these treatments plus radiotherapy. Researchers will be looking for a molecular finger print of each patient"s cancer to try and identify patients most likely to benefit from radiotherapy. Professor Ian Kunkler, from the Edinburgh Cancer Research Centre at the University of Edinburgh, said: "China is experiencing a rapidly rising incidence of breast cancer, particularly in its urban populations. The results of this trial will be applicable to large numbers of people and could demonstrate differences in breast cancer that aren"t found elsewhere. "We also hope that this is just the first in many research collaborations with Chinese cancer centres. We have much to learn about these diseases and by working with on this scale we can get scientific answers more quickly." The trial is being run in conjunction with the Breast International Group, which facilitates cooperation in large breast cancer trials. It is funded by a one million Hong Kong dollar donation by the W & E Davies Charitable Foundation. Anna Smyth University of Edinburgh


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009